November 5, 2019 07:32 AM ESTUpdated 10:38 AM
R&D

Unum drops an­oth­er pro­gram for trou­bled PhI ther­a­py, mov­ing its eggs to the sol­id tu­mor bas­ket

Amber Tong

Sev­er­al months af­ter Unum Ther­a­peu­tics ran in­to a sec­ond safe­ty cri­sis sur­round­ing its pre­mier Phase I ther­a­py, the biotech is putting an­oth­er AC­TR087 tri­al to bed.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times